International Stem Cell Corp. is a clinical stage biotechnology company, which engages in the development of therapeutic and biomedical products. It operates through the following segments: Cosmetic Market, Biomedical Market, and Therapeutic Market. The Cosmetic Market segment develops, manufactures, and markets a cosmetic skin care products based on the company's proprietary parthenogenetic stem cell technology and targeted small molecule technology. The Biomedical Market segment involves in the development, manufacture, and commercialization of primary human cell research products. The Therapeutic Market segment focuses on the research and development of human parthenogenetic stem cells for the treatment of diseases of the central nervous system, liver diseases, and is currently conducting clinical trials for the treatment of Parkinson's disease. The company was founded by William B. Adams, Kenneth C. Aldrich, and Gregory S. Keller on August 17, 2001 and is headquartered in Carlsbad, CA.
Company profile
Ticker
ISCO
Exchange
Website
CEO
Andrey Semechkin
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
BTHC III INC.
SEC CIK
Corporate docs
IRS number
204494098
ISCO stock data
Latest filings (excl ownership)
DEF 14A
Definitive proxy
25 Apr 24
S-8
Registration of securities for employees
28 Mar 24
10-K
2023 FY
Annual report
28 Mar 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
DEF 14C
Information statement
27 Sep 23
8-K
Entry into a Material Definitive Agreement
18 Sep 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
21 Jun 23
10-Q
2023 Q1
Quarterly report
12 May 23
DEF 14A
Definitive proxy
28 Apr 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.43 mm | 1.43 mm | 1.43 mm | 1.43 mm | 1.43 mm | 1.43 mm |
Cash burn (monthly) | (no burn) | (no burn) | 32.33 k | 14.83 k | (no burn) | (no burn) |
Cash used (since last report) | n/a | n/a | 222.34 k | 102.00 k | n/a | n/a |
Cash remaining | n/a | n/a | 1.21 mm | 1.33 mm | n/a | n/a |
Runway (months of cash) | n/a | n/a | 37.4 | 89.5 | n/a | n/a |
Institutional ownership, Q4 2022
0.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 4.00 k |
Total shares | 20.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Accel Wealth Management | 20.00 | $4.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
6 Nov 23 | Russell Kern | Stock Option Common Stock | Grant | Acquire A | No | No | 0.12 | 2,000,000 | 240.00 k | 2,000,000 |
6 Nov 23 | Andrey Semechkin | Stock Option Common Stock | Grant | Acquire A | No | No | 0.12 | 500,000 | 60.00 k | 500,000 |
14 Jun 23 | Maier Paul V | Stock Option Common Stock | Grant | Acquire A | No | No | 0.14 | 445,205 | 62.33 k | 445,205 |
14 Jun 23 | Maier Paul V | Stock Option Common Stock | Grant | Acquire A | No | No | 0.14 | 30,000 | 4.20 k | 30,000 |
14 Jun 23 | Russell Kern | Stock Option Common Stock | Grant | Acquire A | No | No | 0.14 | 500,000 | 70.00 k | 500,000 |
14 Jun 23 | Don Wright | Stock Option Common Stock | Grant | Acquire A | No | No | 0.14 | 445,205 | 62.33 k | 445,205 |
14 Jun 23 | Don Wright | Stock Option Common Stock | Grant | Acquire A | No | No | 0.14 | 30,000 | 4.20 k | 30,000 |